Vyndaqel (Pfizer) is expected to face US generic competition from 2028. Pfizer 10-K: US basic patent 2026, with an extension to 2028 pending. Sales are the Vyndaqel family (Vyndaqel and Vyndamax), for a rare heart disease.
Vyndaqel's US exclusivity date is based on patent-expiry estimate. It is estimated from patent expiry rather than a fixed entry date, so it may move as patents are challenged or extended. It is a small-molecule drug, so copies are generics. Generic launches usually take most of the US volume within months.
Among past small-molecule drugs facing generics: Tecfidera's US sales fell to 21% of their 2019 level in its first full year of generics (2021); Revlimid's US sales fell to 96% of their 2021 level in its first full year of generics (2022) and 57% two years later. Where settlements cap generic volumes, as with Revlimid, the decline is slower. See how past cliffs played out →
Filed with the FDA Several generic makers filed from June 2023 for both versions (Vyndaqel and Vyndamax). Pfizer and Scripps Research sued in August 2023 over the compound, treatment and crystal-form patents; Pfizer does not name the filers.
| Company (product) | Stage |
|---|---|
| Several generic makers (not named by Pfizer) | Generics filed; in litigation |
Checked September 2026. Sources: Pfizer 10-K 2025
Vyndaqel is 10% of Pfizer's 2025 revenue ($6.4B of $62.6B). With Ibrance, Xtandi, Eliquis and Prevnar 20, the drugs tracked here add up to 43% of Pfizer's revenue losing US exclusivity by 2035. Eliquis and Xtandi are Pfizer's reported alliance and product revenue ($8.0B, $2.2B).
Bars show each company's tracked drugs as a share of its total 2025 revenue. Vyndaqel is highlighted.